Hormonal Production Articles & Analysis

1 news found

Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy

Almost 70% of breast cancers are hormone-receptor positive. The majority of these patients are receiving well-established adjuvant endocrine therapy (with the objective of reducing hormonal levels) for at least five years to reduce the recurrence of breast cancer and improving associated mortality. ...

Oct. 17, 2022

ByBayer AG

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you